Studying biological markers in children and young adults with soft tissue sarcoma
Studies tumor and blood samples from young patients with soft tissue sarcoma to predict outcomes.
Plain-language title generated from the registry record
Registry title: Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas
Key facts
- Where
- Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Poitiers, Rennes, Rouen, Saint-Denis, Saint-Etienne, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy, and Villejuif, FranceSee the 28 sites
Where in France
- CHU AmiensAmiens, FranceNo longer taking part
- CHU AngersAngers, FranceNo longer taking part
- CHU BesançonBesançon, FranceNo longer taking part
- CHU PellegrinBordeaux, FranceNo longer taking part
- CHRU BrestBrest, FranceNo longer taking part
- CHU CaenCaen, FranceNo longer taking part
- CHU Clermont-FerrandClermont-Ferrand, FranceNo longer taking part
- CHU DijonDijon, FranceNo longer taking part
- Chu GrenobleGrenoble, FranceNo longer taking part
- Centre Oscar LambretLille, FranceNo longer taking part
- CHU LimogesLimoges, FranceNo longer taking part
- IHOPe - CENTRE LEON BERARDLyon, FranceNo longer taking part
- Chu La Timone - Hopital EnfantsMarseille, FranceNo longer taking part
- CHU MontpellierMontpellier, FranceNo longer taking part
- CHU Nantes Hôpital Mère-EnfantNantes, FranceNo longer taking part
- CHU NiceNice, FranceNo longer taking part
- Ap-Hp - Hopital TrousseauParis, FranceNo longer taking part
- Institut CurieParis, FranceNo longer taking part
- CHU PoitiersPoitiers, FranceNo longer taking part
- CHU de Rennes- Hôpital SudRennes, FranceNo longer taking part
- CHU RouenRouen, FranceNo longer taking part
- Chr Felix GuyonSaint-Denis, FranceNo longer taking part
- CHU Saint-EtienneSaint-Etienne, FranceNo longer taking part
- CHU Strasbourg - Hôpital HautepierreStrasbourg, FranceNo longer taking part
- CHU ToulouseToulouse, FranceNo longer taking part
- CHU Tours Hôpital ClochevilleTours, FranceNo longer taking part
- CHU NANCY- Hôpital d'EnfantsVandœuvre-lès-Nancy, FranceNo longer taking part
- Gustave RoussyVillejuif, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut Curie
- Trial code
- NCT07924384
- Record updated
- 9 November 2026
- Original description
The goal of this study is to better understand biological characteristics of non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), a rare group of cancers that affect children, adolescents, and young adults. Researchers also aim to identify factors that could help predict how the disease will behave and respond to treatment.Read full original descriptionShow less
Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas
The goal of this study is to better understand biological characteristics of non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), a rare group of cancers that affect children, adolescents, and young adults. Researchers also aim to identify factors that could help predict how the disease will behave and respond to treatment.
The main questions it aims to answer are:
* Can advanced molecular analyses improve the classification and diagnosis of NRSTS? * Can blood- and tumor-based biomarkers help predict outcomes and detect relapse earlier? * Can researchers identify biological features that may guide future personalized treatments?
Participants aged 0 to 25 years with a recent diagnosis of NRSTS will take part in the prospective study. Researchers will collect archived tumor samples and blood samples during routine follow-up (approximately every 3 to 4 months) and will analyze these samples using advanced laboratory techniques. Clinical information will also be collected over a follow-up period of up to 4 years.
150 participants will be enrolled in the prospective part from 28 investigating centers across France.
Tumor samples already collected as part of your care, together with blood samples taken during follow-up visits, will be stored for future researches.
Inclusion: Patients with local diagnosis of intermediate or malignant NRSTS, at the time of initial diagnosis only; Localized or metastatic disease; Age: 0-25 years; Whatever strategy is decided (observation, surgery, chemotherapy, radiotherapy, other systemic therapies); Within the 3 months after initial diagnosis; Written informed consent from adult patients, or the 2 parents/legal representatives. Assent from minor patients should be verified; Availability of archived tissue samples. Adult participants or parents must be willing to provide archival tissue. A minimum of 1 FFPE block / 1 HE slide with IHC slides available is required; Patient affiliated to a health insurance system.
Exclusion: Any significant medical, psychological, social or geographic conditions that, in the opinion of the Investigator, would impair study participation or cooperation; NRSTS at relapse; Patients deprived of their liberty or under guardianship.